- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00099645
Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People
A Randomized, Placebo-Controlled, Phase I/II Trial of the Anti-HIV Activity and Safety of VGX-410 (Mifepristone) at Three Dose Levels in HIV-1 Infected Subjects
The purpose of this study is to determine the anti-HIV activity and safety of 3 different doses of mifepristone (also known as VGX-410 and RU486) in HIV infected people.
Hypothesis: Mifepristone will be generally safe (no serious adverse effects) and well tolerated.
Descripción general del estudio
Descripción detallada
Mifepristone is a potent anti-glucocorticoid compound that effectively inhibits replication of both laboratory and clinical HIV isolates in vitro. This study will evaluate the anti-HIV activity and safety of 3 different doses of mifepristone in HIV infected people.
This study will last approximately 2 months. Participants will be randomly assigned to one of 4 study arms, and will receive either mifepristone or placebo daily for 28 days. Arm A participants will receive one of three doses of placebo; Arm B participants will receive 75 mg mifepristone; Arm C participants will receive 150 mg mifepristone; and Arm D participants will receive 225 mg mifepristone. A thorough neck and thyroid examination will be performed within 30 days prior to study entry. Blood collection and vital signs measurement will occur at study entry and Days 3, 7, 14, 21, 28, and 56. Urine collection and pill counts will also be done at some study visits.
Tipo de estudio
Inscripción
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Torrance, California, Estados Unidos, 90502-2052
- Harbor-UCLA Med. Ctr. CRS
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20007
- Georgetown University CRS (GU CRS)
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455-0392
- University of Minnesota, ACTU
-
-
Missouri
-
Saint Louis, Missouri, Estados Unidos, 63108-2138
- Washington U CRS
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Unc Aids Crs
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- The Ohio State Univ. AIDS CRS
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Hosp. of the Univ. of Pennsylvania CRS
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Univ. of Pennsylvania Health System, Presbyterian Med. Ctr.
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213-2582
- Pitt CRS
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- University of Washington AIDS CRS
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- HIV-1 infected
- CD4 count of 350 cells/mm3 or more within 90 days prior to study entry
- HIV-1 viral load of 2000 copies/ml or more within 90 days prior to study entry
- Willing to use acceptable forms of contraception during the study and for 30 days after stopping study medication
- If currently taking precautionary concomitant medications, must be on stable doses for more than 8 weeks prior to study entry and have no plans to change medications or doses for the duration of the study
- Body weight at least 40 kg (88 lbs) within 90 days prior to study entry
Exclusion Criteria:
- Antiretroviral treatment (ART) within 16 weeks prior to study entry, or intend to start ART within 60 days after entry
- Adrenal disorders
- History of autoimmune endocrine disease in self or family
- History of active hepatitis B or C
- Current treatment for hepatitis B or C
- Moderate to severe liver disease
- Blood disorders or current anticoagulant therapy
- Prior pituitary tumor, surgery, radiation treatment, or pituitary failure
- Moderate to large goiters or thyroid nodules
- Diabetes mellitus
- Unusual uterine bleeding within 12 months prior to study entry
- Current hormonal contraception or intrauterine (IUD) use, including progesterone-containing vaginal rings
- Pregnancy within 90 days prior to study entry
- Breast-feeding
- Drugs that act as inhibitors or inducers of metabolism by cytochrome P450 3A4
- Systemic corticosteroids or hormonal agents within 90 days prior to study entry
- Any immunomodulator, HIV vaccine, or investigational therapy within 90 days prior to study entry
- Any vaccination within 30 days prior to study entry
- Systemic cytotoxic chemotherapy within 90 days prior to study entry
- History of allergy to mifepristone or the study formulations
- Current drug or alcohol abuse that, in the opinion of the investigator, may interfere with the study
- Any other conditions that may interfere with participant evaluation during the study
- Serious illness requiring systemic treatment or hospitalization. Patients who complete therapy or are clinically stable on therapy for at least 14 days prior to study entry are not excluded.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
Changes in HIV-1 viral load from baseline to Days 14 and 28
|
Medidas de resultado secundarias
Medida de resultado |
---|
Within 28 days on study, occurrence of toxicity, rash, and symptoms of adrenal insufficiency, including fatigue, nausea, anorexia, vomiting, and dizziness
|
changes from baseline viral load on Days 7, 14, 21, 28, and 56
|
pre-dose concentrations of mifepristone on Days 14 and 28 and serum level of alpha-1 acidic glycoprotein (AAG) at Day 0
|
percentage and counts of CD4 and CD8 cells at baseline and on Days 14, 28, and 56
|
Vpr amino acid sequences on Days 0, 14, 28, and 56
|
comparison of the magnitude and diversity of effector T cell response to HIV antigens at Days 0, 28, and 56
|
change in fasting concentrations of plasma insulin, free fatty acids, high-density lipoprotein (HDL) cholesterol and triglycerides, and in insulin sensitivity between Days 0 and 28
|
Colaboradores e Investigadores
Investigadores
- Silla de estudio: Michael F. Para, MD, Ohio State University
Publicaciones y enlaces útiles
Publicaciones Generales
- Schafer E, Wagner M, and Ayyavoo V. Antiviral Effects of Mifepristone and its Analogs on HIV-1 Vpr-Induced Virus Replication. 11th Conference on Retroviruses and Opportunistic Infections. February 2004.
- Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, Williams WV, Green DR, Weiner DB. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med. 1997 Oct;3(10):1117-23. doi: 10.1038/nm1097-1117.
- Para MF, Schouten J, Rosenkranz SL, Yu S, Weiner D, Tebas P, White CJ, Reeds D, Lertora J, Patterson KB, Daar ES, Cavert W, Brizz B; ACTG A5200 Team of the ACTG. Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):491-5. doi: 10.1097/QAI.0b013e3181d142cb.
Fechas de registro del estudio
Fechas importantes del estudio
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
- Efectos fisiológicos de las drogas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Antagonistas de hormonas
- Agentes Anticonceptivos Hormonales
- Agentes anticonceptivos
- Agentes de control reproductivo
- Anticonceptivos Orales
- Agentes anticonceptivos femeninos
- Anticonceptivos, Orales, Sintéticos
- Agentes abortivos
- Agentes luteolíticos
- Agentes abortivos, esteroides
- Anticonceptivos Postcoitales Sintéticos
- Anticonceptivos Postcoitales
- Agentes inductores de la menstruación
- Mifepristona
Otros números de identificación del estudio
- A5200
- 10186 (Otro identificador: CTEP)
- ACTG A5200
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infecciones por VIH
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán